Stocks · News reference
NovoCure shares are trading higher after the company reported better-than-expected Q2 financial results and raised its FY26 sales guidance above estimates.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
8-K filing — NovoCure Ltd (NVCR)
Filed: 2026-10-01 AccNo: 0001645113-26-000071 Size: 163 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Novocure Reported Unauthorized Systems Access In Mid-August 2026, Exposing Internal Patient ID Numbers For Over 1,400 U.S. Records; No Medical Device Access Obtained, Operations, Systems Fully Functional
NovoCure's Strongest Quarter Ever Isn't Enough to Stop NVCR Stock From Sliding
NovoCure revenue outlook rises after a Q2 beat, stronger patient growth, pipeline progress and planned trial savings.